8th DDR Inhibitors Summit 2025

Making Strides in Targeting PARP, ATR, ATM, WEE1 & POLθ AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors and innovative combination therapies. At the same time, Roche and Novartis are pushing their own DDR-targeting pipelines, exploring emerging targets such as USP1 and WRN – these combined efforts are making DDR inhibitor drug development an increasingly dynamic and transformative area. Additionally, biotechs like Artios Pharma and Repare Therapeutics are expanding the field with cutting-edge research and clinical programs, using innovative platforms to understand cancer biology, discover novel DDR targets, and identify patients most likely to benefit from the treatments. In light of these advancements, the 8th Annual DDR Inhibitors Summit, returning to Boston this January, is the community hotspot for biopharma drug developers and researchers to collaborate on advancing DDR therapeutics. Join 100+ experts from discovery, preclinical, translational, regulatory, and clinical roles as they unite to harness the potential of DDR inhibitors for cancer treatment and enhance patient outcomes. What’s New for 2025? - Hear From Leading Voices: Insight from industry leaders such as Lisa Mahnke (President, Board Member, Chief Executive & Medical Officer, Nerviano Medical Sciences), Harry Raftopoulos (Senior Vice President, Clinical Research, Head of Oncology, Eikon Therapeutics), and Kirk Tanner (Chief Scientific Officer, National Brain Tumor Society) sharing their experiences in advancing DDR therapeutics - Evaluate Novel DDR Pathways: Presentations on innovative approaches like Eisbach Bio’s first-in-class allosteric inhibitor of ALC1, ForX Therapeutics’ potent PARG inhibitor, and CTX-439, and Chordia Therapeutics’ first-in-class CDK12 inhibitor, highlighting their potential in clinical applications - Explore Innovative Drug Discovery & Development: Insights on AI-powered methodologies for identifying synthetic lethal DDR targets from Insilico Medicine and assessing the patient-selection capabilities of of Allarity Therapeutic’s Drug Response Predictor (DRP) diagnostic

Event Links

Website: https://go.evvnt.com/2658144-0

Tickets: https://go.evvnt.com/2658144-2

Brochure: https://go.evvnt.com/2658144-3

Read More

View Less